A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-2845, in Patients With Advanced or Treatment Refractory Haematological Diseases or Lymphoid Malignancies
CHR-2845 is a novel type of histone deacetylase inhibitor (HDACi) for use in cancer that, in
addition to having broad ranging anti-proliferative activity against transformed cells, is
designed to have an increased therapeutic window against diseases which involve cells of the
monocyte-macrophage lineage. There are several HDACi's in clinical development and one,
SAHA (Vorinostat, Zolinza®), has recently been approved for use in the treatment of
cutaneous T-cell lymphoma. CHR-2845 is a cell-permeant ester that is metabolised to give an
active acid, CHR-2847, which selectively accumulates in monocytes and macrophages. This
results in a 20-100 fold increase in anti-proliferative potency of CHR-2845 for monocytic
over non-monocytic tumour cells. This selectivity should lead to an increased therapeutic
window in haematological malignancies involving cells of the monocyte lineage (AML M4, AML
M5 and CMML). In addition, there is increasing evidence that monocytes and macrophages
associated with some haematological tumours (tumour-associated macrophages (TAMs)) are
involved in supporting the growth and spread of the tumour. This clinical trial will focus
on haematological and lymphoid malignancies with the intention of evaluating the safety and
tolerability of CHR-2845. Additionally it will compare response in patients where
monocytes/macrophages are important disease drivers, with the response in other patients.
This will allow an early determination of the potential improvement in therapeutic window
afforded by the monocyte/macrophage directed HDACi activity.
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the safety, tolerability, dose-limiting toxicities (DLT), maximum acceptable dose (MAD) and maximum tolerated dose (MTD)
28 days
Yes
Bob Löwenberg, M.D
Principal Investigator
Erasmus Medical Center
Belgium: Federal Agency for Medicinal Products and Health Products
CHR-2845-001
NCT00820508
December 2008
July 2011
Name | Location |
---|